Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4843-

  Kaufman, Howard L ^a   Lenz, Heinz Josef ^b   Marshall, John ^c   Singh, Deepti ^d   Garett, Chris ^f   Cripps, Christine ^g   Moore, Malcolm ^h   Von Mehren, Margaret ^j   Dalfen, Richard ^k   Heim, William J ^l   Conry, Robert M ^m   Urba, Walter J ⁿ   Benson III, Al B ^e   Yu, Maria ⁱ   Caterini, Judy ⁱ   Kim Schulze, Seunghee ^a   DeBenedette, Mark ⁱ   Salha, Danielle ⁱ   Vogel, Thorsten ⁱ   Elias, Ileana ⁱ   Berinstein, Neil L ⁱ   more..

^a Och Spine at New York Presbyterian Hospitals

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g OTTAWA REGIONAL CANCER CENTRE   (Canada)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ Sanofi Pasteur   (Canada)

^j FOX CHASE CANCER CENTER   (United States)

^k MCGILL UNIVERSITY   (Canada)

^l Hematology and Oncology Associates of Northeastern Pennsylvania   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ EARLE A CHILES RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC CEA B7.1 VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; TETANUS TOXOID; UNCLASSIFIED DRUG; ALVAC VACCINE; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CAMPTOTHECIN; DRUG DERIVATIVE; VIRUS VACCINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPOKALEMIA; HYPONATREMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; AGED; CHEMISTRY; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ANTIGENS, CD80; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 51049083164     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0276     Document Type: Article

References (31)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Horig H, Lee DS, Conkright W, et al. Phase 1 clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14.
4. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219-28.
5. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15.
6. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
7. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:1407-12.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343: 905-14.
10. Horig H, Medina FA, Conkright WA, et al. Strategies for cancer therapy using carcinoembryonic antigen vaccines. Expert Rev Mol Med 2000;2:1-24.
11. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3:2439-49.
12. Zaremba S, Barzaga E, Zhu M, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-7.
13. Musey L, Ding Y, Elizaga M, et al. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 2003;171:1094-101.
14. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 1996; 93:11349-53.
15. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17: 332-7.
16. Liu B, Podack ER, Allison JP, et al. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 1996; 156:1117-25.
17. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.
18. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994;6:414-9.
19. Akagi J, Nakagawa K, Egami H, et al. Induction of HLA-unrestricted and HLA-class-ll-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol Immunother 1998; 47:21-31.
20. La Rosa C, Wang Z, Brewer JC, et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002;100:3681-9.
21. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7.
22. Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003:30:30-6.
23. Slingluff CL, Jr., Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001;7:3012-24.
24. Gattinoni L, Powell DJ, Jr., Rosenberg SA, et al. Adoptive immunotherapy for cancer; building on success. Nat Rev Immunol 2006;6:383-93.
25. Cheng H, Liu Y, Liu S, et al. 5-Fluorouracil enhances apoptosis sensitivity of T lymphocytes mediated by CD3ε. Cell Biochem Funct 2004;22:187-95.
26. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004; 172:4599-608.
27. Melichar B, Touskova M, Vesely P. Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer. Hepatogastroenterology 2002;49:967-70.
28. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 1997;9:339-46.
29. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
30. Zoller M. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host. J Immunol 2003;171:6941-53.
31. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.